Kura, Kyowa Kirin Launch AML Trial for Dual Gene Mutations
Kura Oncology and Kyowa Kirin have dosed the first patient in a new cohort of the KOMET-007 study assessing...
Jon Napitupulu
Surging Aerska Gets $21M for Pioneering RNAi Brain Therapy
Aerska has raised $21 million in seed financing to develop systemically administered RNA interference medicines for neurological diseases, built...
Avalo Therapeutics Expands Leadership with Key Appointments
Avalo Therapeutics has expanded its leadership bench, appointing Taylor Boyd as chief business officer and Ashley Ivanowicz as senior...
e-therapeutics Relaunches as Tangram, Unveils LliBRA OS
Tangram Therapeutics, formerly e-therapeutics, has relaunched with a sharpened focus on RNA interference and unveiled LLIBRA OS, a next-generation...
RetinalGenix, Rgen Announce Collaboration for Early Detection
RetinalGenix Technologies and RGEN Inc. have formed a strategic partnership to integrate high-resolution retinal imaging with CLIA-certified DNA genotyping,...
Hinge Bio, Kyorin Collaborate on Autoimmune Drug for Japan
Hinge Bio has signed a collaboration and license agreement with Kyorin Pharmaceutical for HB2198, a multispecific antibody targeting CD19...
Nanobiotix Updates Activities, H1 2025 Financial Results
Nanobiotix reported a step-change half year marked by clinical expansion with JNJ-1900 (NBTXR3), regulatory harmonization in Europe, and a...
FDA Approves Novartis’s Rhapsido®, an Oral CSU Treatment
Novartis has secured FDA approval for Rhapsido (remibrutinib), an oral Bruton’s tyrosine kinase inhibitor indicated for adults with chronic...
Revolution Medicines Announces New Chief Development Officer
Revolution Medicines has created a chief development officer role and named Alan Sandler, M.D., to the post, while simultaneously...
Surging Hope: Rademikibart Data Presented at ERS Congress
Connect Biopharma presented new post-hoc analyses at ERS 2025 showing that rademikibart, its investigational anti–IL-4Rα antibody, delivered rapid and...